Literature DB >> 18380605

Tularemia: current diagnosis and treatment options.

Matthew J Hepburn1, Andrew J H Simpson.   

Abstract

Tularemia is an infection caused by Francisella tularensis with a worldwide distribution and diverse clinical manifestations. Limitations in both culture and serologic testing have led to substantial research into new diagnostic techniques and their clinical application, with PCR testing as the best example. This review focuses on the utility of culture, PCR and serologic testing for tularemia. In addition, we also review the evidence to support different therapeutic options for tularemia, highlighting both the most effective supporting evidence for therapeutic recommendations as well as gaps in current knowledge. We conclude the article with suggestions regarding potential areas for future research.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18380605     DOI： 10.1586/14787210.6.2.231

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN： 1478-7210            Impact factor:   5.091


  35 in total

1.  Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.

Authors:  Shahila Mehboob; Kirk E Hevener; Kent Truong; Teuta Boci; Bernard D Santarsiero; Michael E Johnson
Journal:  J Med Chem       Date:  2012-06-08       Impact factor: 7.446

2.  Determination of absolute configuration and binding efficacy of benzimidazole-based FabI inhibitors through the support of electronic circular dichroism and MM-GBSA techniques.

Authors:  Jinhong Ren; Tina L Mistry; Pin-Chih Su; Shahila Mehboob; Robel Demissie; Leslie Wo-Mei Fung; Arun K Ghosh; Michael E Johnson
Journal:  Bioorg Med Chem Lett       Date:  2018-04-22       Impact factor: 2.823

3.  Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.

Authors:  Yan-Yan Zhang; Yong Liu; Shahila Mehboob; Jin-Hua Song; Teuta Boci; Michael E Johnson; Arun K Ghosh; Hyunyoung Jeong
Journal:  Xenobiotica       Date:  2013-10-30       Impact factor: 1.908

4.  Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).

Authors:  Michelle Nelson; Mark S Lever; Rachel E Dean; Peter C Pearce; Daniel J Stevens; Andrew J H Simpson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

5.  Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Authors:  Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

6.  [Secondary acquired lacrimal duct obstruction and cervical lymphadenopathy].

Authors:  J Heichel; E Luci; H-G Struck; U Siebolts; C Wickenhauser; S Plontke; A Viestenz; G Götze
Journal:  HNO       Date:  2018-11       Impact factor: 1.284

7.  Sensitive Detection of Francisella tularensis Directly from Whole Blood by Use of the GeneXpert System.

Authors:  Padmapriya P Banada; Srinidhi Deshpande; Soumitesh Chakravorty; Riccardo Russo; James Occi; Gabriel Meister; Kelly J Jones; Carl H Gelhaus; Michelle W Valderas; Martin Jones; Nancy Connell; David Alland
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

8.  Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.

Authors:  Elamparithi Jayamani; Nagendran Tharmalingam; Rajmohan Rajamuthiah; Jeffrey J Coleman; Wooseong Kim; Ikechukwu Okoli; Ana M Hernandez; Kiho Lee; Gerard J Nau; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

9.  Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Authors:  Michael D Valentino; Lucinda L Hensley; Denise Skrombolas; Pamela L McPherson; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Mol Immunol       Date:  2009-02-23       Impact factor: 4.407

10.  Evaluation of In-House and Commercial Serological Tests for Diagnosis of Human Tularemia.

Authors:  Hadjila Yanes; Aurélie Hennebique; Isabelle Pelloux; Sandrine Boisset; Dominique J Bicout; Yvan Caspar; Max Maurin
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.